Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study

  • Sala-Vila, Aleix
  • Tristão Pereira, Catarina
  • Lázaro, Iolanda
  • Shekari, Mehrnaz
  • Fernández-Pena, Alberto
  • Monereo-Sánchez, Jennifer
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • Ibáñez, Borja
  • Fuster, Valentín
  • Cortes-Canteli, Marta
Background: Excess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown. Objectives: This study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline. Methods: We studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral 18F-fluorodeoxyglucose (FDG) positron emission tomography (4.9 y of follow-up time). Dietary data were derived from a validated food-frequency questionnaire. Associations were assessed using region-of-interest and voxelwise multiple regression models as well as mediation analysis. Results: Cross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA concentrations were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA concentrations. Conclusions: RBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318., The Progression of Early Subclinical Atherosclerosis study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Santander Bank, and also receives funding from the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033) and is supported by the Carlos III Institute of Health (ISCIII), the Ministry of Science and Innovation, and the Pro CNIC Foundation. AS-V was supported by ISCIII, through the project PI22/00071, co-funded by European Regional Development Fund “Investing in your future.” CT-P was supported by a “la Caixa” Foundation fellowship (LCF/BQ/DI19/11730052). BI was supported by the European Commission (ERC-CoG 819775, and H2020-HEALTH 945118), the Spanish Ministry of Science and Innovation (PID2019-110369RB-I00), and the Community of Madrid (P2022/BMD-7403, RENIM-CM). Acknowledgment is made to the Sephardic Foundation on Aging and other donors of the Alzheimer’s Disease Research (Grant Number A2022034S), a program of the BrightFocus Foundation, for the partial support of this research. This work was supported by the Cardiovascular Risk Factors and Brain Health Program at CNIC. The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.
Repisalud
Publication Artículo científico (JournalArticle)

Influence of Subclinical Atherosclerosis Burden and Progression on Mortality.

  • Fuster, Valentin
  • García-Álvarez, Ana
  • Devesa, Ana
  • Mass, Virginia
  • Owen, Ruth
  • Quesada, Antonio
  • Fuster, José J
  • García-Lunar, Inés
  • Pocock, Stuart
  • Sánchez-González, Javier
  • Sartori, Samantha
  • Peyra, Carlos
  • Andres, Vicente
  • Muntendam, Pieter
  • Ibanez, Borja
Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality. A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable. Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P < 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm change; P = 0.01). Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.
Repisalud
Publication Artículo científico (JournalArticle)

Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity.

  • Díaz-Guerra, Anabel
  • Clemente-Moragón, Agustín
  • Pollán, Ángela
  • López-Palomar, Lucía
  • Cádiz, Laura
  • Ibáñez, Borja
Anthracyclines remain a cornerstone of treatment for many cancer types; however, their cardiotoxic potential leads to cardiac dysfunction in a substantial proportion of patients, ultimately compromising long-term quality of life. Few strategies have proven effective in preventing anthracycline-induced cardiotoxicity (AIC). Among them, remote ischemic conditioning (RIC) has emerged as one of the most promising, having shown robust cardioprotective potential in preclinical studies and currently being evaluated in clinical trials. However, it remains unclear whether this intervention, while protecting the heart, could also inadvertently protect tumors from the cytotoxic effects of anthracyclines, thereby reducing their antitumor efficacy. In this study, we investigated whether RIC protects against AIC in a tumor-bearing mouse model, allowing simultaneous assessment of both cardiac and tumoral responses. Cutaneous tumors were induced in CD1 mice using a DMBA/TPA protocol, followed by five weekly intraperitoneal injections of doxorubicin (5 mg/kg). Mice bearing tumors were randomized to receive doxorubicin alone or in combination with weekly RIC (three cycles of 5 min hindlimb ischemia/reperfusion). Longitudinal echocardiography was used to assess cardiac function, while tumor growth, survival, and body weight were monitored throughout the protocol. Doxorubicin treatment reduced overall survival, inhibited tumor growth, and induced left ventricular systolic dysfunction and cardiac atrophy compared with untreated controls. RIC preserved left ventricular ejection fraction, partially attenuated early left ventricular atrophy, and showed a trend towards improved survival, without attenuating the antitumor efficacy of doxorubicin, as tumor suppression remained comparable between treatment groups. These findings demonstrate that RIC preserves cardiac systolic function during anthracycline chemotherapy in tumor-bearing mice without impairing the antitumor efficacy of the drug. The results support RIC as a simple, safe, and low-cost non-pharmacological strategy to mitigate AIC with potential translational relevance for oncology patients.
Repisalud
Publication Artículo científico (JournalArticle)

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

  • Ghigo, Alessandra
  • Ameri, Pietro
  • Asnani, Aarti
  • Bertero, Edoardo
  • de Boer, Rudolf A
  • Farmakis, Dimitrios
  • González, Arantxa
  • Heymans, Stephane
  • Ibáñez, Borja
  • López-Fernández, Teresa
  • Lyon, Alexander R
  • Pollesello, Piero
  • Rakisheva, Amina
  • Stellos, Konstantinos
  • Streckfuss-Bömeke, Katrin
  • Tocchetti, Carlo Gabriele
  • Thum, Thomas
  • van der Meer, Peter
  • Van Rooij, Eva
  • Ponikowski, Piotr
  • Metra, Marco
  • Rosano, Giuseppe
  • Van Linthout, Sophie
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Repisalud
Publication Artículo científico (JournalArticle)

Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis.

  • Devesa, Ana
  • Fuster, Valentin
  • Vazirani, Ravi
  • Garcia-Lunar, Ines
  • Oliva, Belen
  • Espana, Samuel
  • Moreno-Arciniegas, Andrea
  • Sanz, Javier
  • Perez-Herreras, Cristina
  • Bueno, Hector
  • Lara-Pezzi, Enrique
  • Garcia-Alvarez, Ana
  • de Vega, Vicente Martínez
  • Fernandez-Friera, Leticia
  • Trivieri, Maria G
  • Fernandez-Ortiz, Antonio
  • Rossello, Xavier
  • Sanchez-Gonzalez, Javier
  • Ibáñez, Borja
OBJECTIVE Experimental evidence suggests that metabolic syndrome (MetS) is associated with changes in cardiac metabolism. Whether this association occurs in humans is unknown. RESEARCH DESIGN AND METHODS 821 asymptomatic individuals from the Progression of Early Subclinical Atherosclerosis (PESA) study (50.6 [46.9-53.6] years, 83.7% male) underwent two whole-body 18F-fluorodeoxyglucose positron emission tomography-magnetic resonance (18F-FDG PET-MR) 4.8 ± 0.6 years apart. Presence of myocardial 18F-FDG uptake was evaluated qualitatively and quantitatively. No myocardial uptake was grade 0, while positive uptake was classified in grades 1-3 according to target-to-background ratio tertiles. RESULTS One hundred fifty-six participants (19.0%) showed no myocardial 18F-FDG uptake, and this was significantly associated with higher prevalence of MetS (29.0% vs. 13.9%, P < 0.001), hypertension (29.0% vs. 18.0%, P = 0.002), and diabetes (11.0% vs. 3.2%, P < 0.001), and with higher insulin resistance index (HOMA-IR, 1.64% vs. 1.23%, P < 0.001). Absence of myocardial uptake was associated with higher prevalence of early atherosclerosis (i.e., arterial 18F-FDG uptake, P = 0.004). On follow-up, the associations between myocardial 18F-FDG uptake and risk factors were replicated, and MetS was more frequent in the group without myocardial uptake. The increase in HOMA-IR was associated with a progressive decrease in myocardial uptake (P < 0.001). In 82% of subjects, the categorization according to presence/absence of myocardial 18F-FDG uptake did not change between baseline and follow-up. MetS regression on follow-up was associated with a significant (P < 0.001) increase in myocardial uptake. CONCLUSIONS Apparently healthy individuals without cardiac 18F-FDG uptake have higher HOMA-IR and higher prevalence of MetS traits, cardiovascular risk factors, and early atherosclerosis. An improvement in cardiometabolic profile is associated with the recovery of myocardial 18F-FDG uptake at follow-up.
Repisalud
Publication Artículo científico (JournalArticle)

The impact of type 2 immunity and allergic diseases in atherosclerosis.

  • Fernández-Gallego, Nieves
  • Castillo-González, Raquel
  • Méndez-Barbero, Nerea
  • López-Sanz, Celia
  • Obeso, David
  • Villaseñor, Alma
  • Escribese, María M
  • López-Melgar, Beatriz
  • Salamanca, Jorge
  • Benedicto-Buendía, Amparo
  • Jiménez-Borreguero, Luis Jesús
  • Ibáñez, Borja
  • Sastre, Joaquín
  • Belver, María Teresa
  • Vega, Francisco
  • Blanco, Carlos
  • Barber, Domingo
  • Sánchez-Madrid, Francisco
  • de la Fuente, Hortensia
  • Martin, Pilar
  • Esteban, Vanesa
  • Jiménez-Saiz, Rodrigo
  • Fernández‐Gallego, Nieves
  • Castillo‐González, Raquel
  • Méndez‐Barbero, Nerea
  • López‐Sanz, Celia
  • Escribese, María M.
  • López‐Melgar, Beatriz
  • Benedicto‐Buendía, Amparo
  • Jiménez‐Borreguero, Luis Jesús
  • Sánchez‐Madrid, Francisco
  • Jiménez‐Saiz, Rodrigo
Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).
Repisalud
Publication Artículo científico (JournalArticle)

Four-Dimensional Magnetic Resonance Pulmonary Flow Imaging for Assessing Pulmonary Vasculopathy in Patients with Postcapillary Pulmonary Hypertension.

  • Nuche, Jorge
  • Ponz, Inés
  • Sánchez Sánchez, Violeta
  • Bóbeda, Javier
  • Gaitán, Ángel
  • López-Linares, Karen
  • García-Cosío, María Dolores
  • Sarnago Cebada, Fernando
  • González, Javier Sánchez
  • Arribas Ynsaurriaga, Fernando
  • Ruíz-Cabello, Jesús
  • Ibáñez, Borja
  • Delgado, Juan F
Noninvasive techniques for diagnosing combined postcapillary pulmonary hypertension (CpcPH) are unavailable. : To assess the diagnostic performance of cardiac magnetic resonance (CMR)-based four-dimensional (4D)-flow analysis in identifying CpcPH. : Prospective observational study of heart failure (HF) patients with suspected pulmonary hypertension (PH) who underwent simultaneous CMR and right heart catheterization. The 4D-flow biomarkers were calculated using an automatic pipeline. A predictive model including 4D-flow biomarkers associated with CpcPH with a -value < 0.20 was built to determine the diagnostic performance of 4D-flow analysis to identify CpcPH. : A total of 46 HF patients (55.4 ± 14 years, 63% male) with confirmed PH (19 [41%] isolated postcapillary PH [IpcPH], 27 [59%] CpcPH) were included. No differences were found in baseline characteristics, echocardiography, or CMR anatomical and functional parameters, except for a higher Doppler-estimated systolic pulmonary pressure and larger pulmonary artery in CpcPH patients. The 4D-flow CMR analysis was performed in 31 patients (67%). The maximal peak velocity (67.1 [62.2-77.5] cm/s-IpcPH vs. 58.2 [45.8-66.0] cm/s-CpcPH; = 0.021) and maximal helicity (339.9 [290.0-391.8]) cm/s-IpcPH vs. 226.0 (173.5-343.7) cm/s-CpcPH; = 0.026) were significantly lower in patients with CpcPH. A maximal multivariable model including sex, maximal average, and peak velocities, Reynolds number, flow rate, and helicity showed fair diagnostic performance (area under the curve: 0.768 [95%-CI: 0.572-0.963]; sensitivity: 100%; specificity: 55%). : In HF patients with PH, 4D-flow-derived maximal peak velocity and maximal helicity were significantly lower in CpcPH patients. A multiparametric model including maximal 4D-flow-derived biomarkers showed good diagnostic performance for identifying CpcPH.
Repisalud
Publication Artículo científico (JournalArticle)

The impact of type 2 immunity and allergic diseases in atherosclerosis.

  • Fernandez-Gallego, Nieves
  • Castillo-Gonzalez, Raquel
  • Mendez-Barbero, Nerea
  • López-Sanz, Celia
  • Obeso, David
  • Villaseñor, Alma
  • Escribese, María M
  • Lopez-Melgar, Beatriz
  • Salamanca, Jorge
  • Benedicto-Buendía, Amparo
  • Jiménez-Borreguero, Luis Jesús
  • Ibáñez, Borja
  • Sastre, Joaquín
  • Belver, María Teresa
  • Vega, Francisco
  • Blanco, Carlos
  • Barber, Domingo
  • Sanchez-Madrid, Francisco
  • de la Fuente, Hortensia
  • Martin, Pilar
  • Esteban, Vanesa
  • Jiménez-Saiz, Rodrigo
Allergic diseases are allergen-induced immunological disorders characterized by the development of type 2 immunity and IgE responses. The prevalence of allergic diseases has been on the rise alike cardiovascular disease (CVD), which affects arteries of different organs such as the heart, the kidney and the brain. The underlying cause of CVD is often atherosclerosis, a disease distinguished by endothelial dysfunction, fibrofatty material accumulation in the intima of the artery wall, smooth muscle cell proliferation, and Th1 inflammation. The opposed T-cell identity of allergy and atherosclerosis implies an atheroprotective role for Th2 cells by counteracting Th1 responses. Yet, the clinical association between allergic disease and CVD argues against it. Within, we review different phases of allergic pathology, basic immunological mechanisms of atherosclerosis and the clinical association between allergic diseases (particularly asthma, atopic dermatitis, allergic rhinitis and food allergy) and CVD. Then, we discuss putative atherogenic mechanisms of type 2 immunity and allergic inflammation including acute allergic reactions (IgE, IgG1, mast cells, macrophages and allergic mediators such as vasoactive components, growth factors and those derived from the complement, contact and coagulation systems) and late phase inflammation (Th2 cells, eosinophils, type 2 innate-like lymphoid cells, alarmins, IL-4, IL-5, IL-9, IL-13 and IL-17).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Anthracycline cardiotoxicity Induces progressive changes in myocardial metabolism and mitochondrial quality control: Novel therapeutic target

  • Díaz-Guerra, Anabel
  • Villena-Gutiérrez, Rocío
  • Clemente-Moragón, Agustín
  • Gómez, Mónica
  • Oliver, Eduardo
  • Fernández-Tocino, Miguel
  • Galán-Arriola, Carlos
  • Cádiz, Laura
  • Ibáñez, Borja
16 p.-8 fig., Background: Anthracycline-induced cardiotoxicity (AIC) debilitates quality of life in cancer survivors. Serial characterizations are lacking of the molecular processes occurring with AIC., Objectives: The aim of this study was to characterize AIC progression in a mouse model from early (subclinical) to advanced heart failure stages, with an emphasis on cardiac metabolism and mitochondrial structure and function., Methods: CD1 mice received 5 weekly intraperitoneal doxorubicin injections (5 mg/kg) and were followed by serial echocardiography for 15 weeks. At 1, 9, and 15 weeks after the doxorubicin injections, mice underwent fluorodeoxyglucose positron emission tomography, and hearts were extracted for microscopy and molecular analysis., Results: Cardiac atrophy was evident at 1 week post-doxorubicin (left ventricular [LV] mass 117 ± 26 mg vs 97 ± 25 mg at baseline and 1 week, respectively; P < 0.001). Cardiac mass nadir was observed at week 3 post-doxorubicin (79 ± 16 mg; P = 0.002 vs baseline), remaining unchanged thereafter. Histology confirmed significantly reduced cardiomyocyte area (167 ± 19 μm2 in doxorubicin-treated mice vs 211 ± 26 μm2 in controls; P = 0.004). LV ejection fraction declined from week 6 post-doxorubicin (49% ± 9% vs 61% ± 9% at baseline; P < 0.001) until the end of follow-up at 15 weeks (43% ± 8%; P < 0.001 vs baseline). At 1 week post-doxorubicin, when LV ejection fraction remained normal, reduced cardiac metabolism was evident from down-regulated markers of fatty acid oxidation and glycolysis. Metabolic impairment continued to the end of follow-up in parallel with reduced mitochondrial adenosine triphosphate production. A transient early up-regulation of nutrient-sensing and mitophagy markers were observed, which was associated with mitochondrial enlargement. Later stages, when mitophagy was exhausted, were characterized by overt mitochondrial fragmentation., Conclusions: Cardiac atrophy, global hypometabolism, early transient-enhanced mitophagy, biogenesis, and nutrient sensing constitute candidate targets for AIC prevention., Dr Ibáñez is supported by the European Commission (grants ERC-CoG 819775 and H2020-HEALTH 945118), the Spanish Ministry of Science, Innovation and Universities (grant PID2022-140176OB-I00), and Comunidad de Madrid through the Red Madrileña de Nanomedicina en Imagen Molecular (grant P2022/BMD-7403 RENIM-CM). Dr Díaz-Guerra’s PhD fellowship is funded by the Spanish Association Against Cancer. Dr Oliver is a Ramón y Cajal fellow (grant RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in Your Future.” Centro Nacional de Investigaciones Cardiovasculares is supported by Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study

  • Sala-Vila, Aleix
  • Tristão Pereira, Catarina
  • Lázaro, Iolanda
  • Shekari, Mehrnaz
  • Fernández-Pena, Alberto
  • Monereo-Sánchez, Jennifer
  • Garcia-Lunar, Ines
  • Perez-Herreras, Cristina
  • Moro, Maria Angeles
  • Garcia-Alvarez, Ana
  • Sánchez González, Javier
  • Gispert, Juan Domingo
  • Ibáñez, Borja
  • Fuster, Valentín
  • Cortes-Canteli, Marta
Background: Excess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown. Objectives: This study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline. Methods: We studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral 18F-fluorodeoxyglucose (FDG) positron emission tomography (4.9 y of follow-up time). Dietary data were derived from a validated food-frequency questionnaire. Associations were assessed using region-of-interest and voxelwise multiple regression models as well as mediation analysis. Results: Cross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA concentrations were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA concentrations. Conclusions: RBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318., The Progression of Early Subclinical Atherosclerosis study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Santander Bank, and also receives funding from the European Regional Development Fund (ERDF–A Way to Build Europe), and the European Social Fund (ESF–Investing in Your Future). CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033) and is supported by the Carlos III Institute of Health (ISCIII), the Ministry of Science and Innovation, and the Pro CNIC Foundation. AS-V was supported by ISCIII, through the project PI22/00071, co-funded by European Regional Development Fund “Investing in your future.” CT-P was supported by a “la Caixa” Foundation fellowship (LCF/BQ/DI19/11730052). BI was supported by the European Commission (ERC-CoG 819775, and H2020-HEALTH 945118), the Spanish Ministry of Science and Innovation (PID2019-110369RB-I00), and the Community of Madrid (P2022/BMD-7403, RENIM-CM). Acknowledgment is made to the Sephardic Foundation on Aging and other donors of the Alzheimer’s Disease Research (Grant Number A2022034S), a program of the BrightFocus Foundation, for the partial support of this research. This work was supported by the Cardiovascular Risk Factors and Brain Health Program at CNIC. The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.